FierceBiotech

BioTime, Inc. Reports Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells

Paper and Related Patent Filings Are a Strategic Step Forward in the Development of the Company's ReCyte(TM) iPS Technology ALAMEDA, Calif., Mar 16, 2010 (BUSINESS WIRE) -- BioTime, Inc., a ...
Business Wire

BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent ...
FiercePharma

BioTime and OncoCyte Corporation Publish Data on the Gene COL10A1 as a Marker and Potential Diagnostic for a Wide Array of Human Cancers

BioTime and OncoCyte Corporation Publish Data on the Gene as a Marker and Potential Diagnostic for a Wide Array of Human Cancers BioTime, Inc.Peter Garcia, 510-521-3390 ext. 367Chief Financial ...
FierceBiotech

BioTime Forms BioTime Acquisition Corporation

BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301 BioTime, Inc. (NYSE MKT: BTX), an Alameda-based company engaged in research and ...
FiercePharma

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.33 Million Grant From Israel’s Office of the Chief Scientist BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. ...
AOL

BioTime Announces the Appointment of Jeffrey Janus as Vice President

Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of ...